Altimmune, Inc. Research And Development Expense

• Altimmune, Inc. showed a decrease of -19.2% in Research And Development Expense from 2024 to 2025.
• This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Altimmune, Inc.'s Research And Development Expense has grown by 218.2%.
• Historical annual values: Fiscal year 2025: $66.43 million | Fiscal year 2024: $82.23 million | Fiscal year 2023: $65.80 million | Fiscal year 2022: $70.54 million | Fiscal year 2021: $74.54 million | Fiscal year 2020: $49.77 million | Fiscal year 2019: $17.77 million | Fiscal year 2018: $18.46 million | Fiscal year 2017: $18.41 million | Fiscal year 2016: $7.22 million | Fiscal year 2015: $5.13 million | Fiscal year 2014: $9.32 million | Fiscal year 2013: $15.29 million | Fiscal year 2012: $19.51 million | Fiscal year 2011: $21.22 million | Fiscal year 2010: $20.88 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026